Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
Chugai Pharmaceutical saw its first-quarter revenue more than double in 2022, buoyed by the government purchase of its COVID-19 antibody cocktail Ronapreve (casirivimab + imdevimab). The Roche group company notched up growth even excluding this factor. In January-March, the drug…
To read the full story
Related Article
- Chugai’s Q1 Profit Drops by Half in Pullback from Alexion Settlement Gain
April 28, 2023
- Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
February 3, 2023
- Chugai Enjoys Big Surge in H1 Earnings on Strong Uptake of New Launches
July 22, 2022
- Chugai Joins Top Ranks in Japan Sales on Ronapreve Boon, Roche Collaboration
February 14, 2022
- Chugai’s Sales and Profit Rose for 5 Years Running, 1 Trillion Yen-Plus Expected in 2022
February 4, 2022
- Chugai’s 9-Month Sales Up 17.5% on Ronapreve, 42.8 Billion Yen Booked in Govt Purchase
October 25, 2021
- Chugai’s H1 Sales Rise on Growth of Tecentriq, Kadcyla
July 27, 2021
- Chugai’s Q1 Sales Slide 5.9% on Drug Price Cuts, Gx, Frontloaded Actemra Exports
April 23, 2021
- Chugai Closes Book with Double-Digit Earnings Growth on Overseas Sales, Royalties
February 5, 2021
BUSINESS
- Japan’s Big 4 Drug Wholesalers See Profit Pressure Intensify in FY2025
May 19, 2026
- Asahi Kasei Starts Japan PIII of Extended Teribone Dosing
May 19, 2026
- Allergan Files Botox Vista for Forehead Wrinkles
May 19, 2026
- Stella Begins Japan PIII of BNCT for Recurrent Glioblastoma
May 19, 2026
- Enhertu Earns 2 US Approvals in HER2-Positive Early Breast Cancer
May 19, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…